We used samples from patients with a history of SARS-CoV-2 infection and controls to show that an autoantibody against ACE2 is present in some patients after infection, that patients that have ACE2 antibodies have lower amounts of soluble ACE2 activity, and that plasma from these patients can inhibit ACE2 activity. Here, ACE2 is linked to infection.